Home » Stocks » Xynomic Pharmaceutical

Xynomic Pharmaceutical Holdings Inc. (XYNO)

Stock Price: $2.08 USD 0.65 (45.63%)
Updated Oct 23, 2020 3:31 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 96.37M
Revenue (ttm) n/a
Net Income (ttm) -25.10M
Shares Out 46.27M
EPS (ttm) -4.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $2.08
Previous Close $1.43
Change ($) 0.65
Change (%) 45.63%
Day's Open 2.08
Day's Range 2.08 - 2.08
Day's Volume 200
52-Week Range 0.2 - 4.29

More Stats

Market Cap 96.37M
Enterprise Value 96.68M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 46.27M
Float 6.40M
EPS (basic) -0.83
EPS (diluted) -4.25
FCF / Share -0.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 622
Short Ratio 0.01
Short % of Float 0.01%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 44.89
Revenue n/a
Operating Income -25.04M
Net Income -25.10M
Free Cash Flow -10.72M
Net Cash -312,239
Net Cash / Share -0.01
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -489.08%
ROE n/a
ROIC 203.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-25.04-28.57-5.45
Net Income-25.10-28.59-5.45
Shares Outstanding32.288.178.83
Earnings Per Share-0.83-3.85-0.76
Operating Cash Flow-10.67-14.72-5.36
Capital Expenditures-0.05-0.18-
Free Cash Flow-10.72-14.90-5.36
Cash & Equivalents0.094.750.10
Total Debt0.40-0.03
Net Cash / Debt-0.314.740.07
Book Value-22.56-20.09-5.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Xynomic Pharmaceutical Holdings Inc.
Country China
Employees 27
CEO Yinglin Mark Xu

Stock Information

Ticker Symbol XYNO
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: XYNO


Xynomic Pharmaceuticals Holdings, a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.